Abstract
Molecules interfering with the Epidermal Growth Factor Receptor (EGFR) have been successfully tested in several human malignancies in the last decade, including non-small cell lung cancer, colo-rectal, pancreatic and head and neck cancer. Particularly, the two most commonly used strategies for blocking EGFR include tyrosine-kinase inhibitors (TKIs) targeting the intracellular domain of the receptor and monoclonal antibodies (MAb) directed against its external portion. One of main goals of researchers is to identify biological predictors of activity or resistance to these agents, both for ethical and pharmacoeconomical reasons. EGFR protein expression assessed by immunohistochemistry does not seem to accurately predict activity of either class of compounds, while presence of EGFR sensitizing mutations, which can be found in significant fractions of NSCLC patients, has been associated with a better outcome in patients receiving EGFR TKIs. Increased EGFR gene copy number could represent a reliable and reproducible tool for proper selection of patients candidate to TKIs or anti-EGFR MAbs. Furthermore, mechanisms of resistance to anti-EGFR strategies are currently being elucidated, allowing identification of subjects who should be excluded from treatment.
Keywords: EGFR, erlotinib, gefitinib, cetuximab, non-small cell lung cancer, colorectal cancer
Current Cancer Therapy Reviews
Title: Optimizing Anti-EGFR Strategies in Cancer Treatment
Volume: 3 Issue: 4
Author(s): Luca Toschi, Giovanna Finocchiaro, Isabella Garassino, Fabio De Vincenzo, Elisabetta Campagnoli, Giovanni Luca Ceresoli, Raffaele Cavina, Paolo Andrea Zucali, Armando Santoro and Federico Cappuzzo
Affiliation:
Keywords: EGFR, erlotinib, gefitinib, cetuximab, non-small cell lung cancer, colorectal cancer
Abstract: Molecules interfering with the Epidermal Growth Factor Receptor (EGFR) have been successfully tested in several human malignancies in the last decade, including non-small cell lung cancer, colo-rectal, pancreatic and head and neck cancer. Particularly, the two most commonly used strategies for blocking EGFR include tyrosine-kinase inhibitors (TKIs) targeting the intracellular domain of the receptor and monoclonal antibodies (MAb) directed against its external portion. One of main goals of researchers is to identify biological predictors of activity or resistance to these agents, both for ethical and pharmacoeconomical reasons. EGFR protein expression assessed by immunohistochemistry does not seem to accurately predict activity of either class of compounds, while presence of EGFR sensitizing mutations, which can be found in significant fractions of NSCLC patients, has been associated with a better outcome in patients receiving EGFR TKIs. Increased EGFR gene copy number could represent a reliable and reproducible tool for proper selection of patients candidate to TKIs or anti-EGFR MAbs. Furthermore, mechanisms of resistance to anti-EGFR strategies are currently being elucidated, allowing identification of subjects who should be excluded from treatment.
Export Options
About this article
Cite this article as:
Toschi Luca, Finocchiaro Giovanna, Garassino Isabella, Vincenzo De Fabio, Campagnoli Elisabetta, Ceresoli Luca Giovanni, Cavina Raffaele, Zucali Andrea Paolo, Santoro Armando and Cappuzzo Federico, Optimizing Anti-EGFR Strategies in Cancer Treatment, Current Cancer Therapy Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339407782497059
DOI https://dx.doi.org/10.2174/157339407782497059 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melanoma
Current Cancer Therapy Reviews Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Altering the Sphingosine-1-Phosphate/Ceramide Balance: A Promising Approach for Tumor Therapy
Current Pharmaceutical Design Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies
Current Drug Delivery Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Host Immune Responses to Aeromonas Virulence Factors
Current Immunology Reviews (Discontinued) Systematic Analysis of the Expression Profile and Prognostic Significance of the IGF2BP Family in Lung Adenocarcinoma
Current Cancer Drug Targets Medical Expert Systems
Current Bioinformatics Eugenol Inhibits the Biological Activities of an Oral Squamous Cell Carcinoma Cell Line SCC9 <i>via</i> Targeting MIF
Anti-Cancer Agents in Medicinal Chemistry Past, Recent Progresses and Future Perspectives of Nanotechnology Applied to Antifungal Agents
Current Drug Metabolism Synthesis and Preliminary Cytotoxicity Studies of 1-[1-(4,5-Dihydrooxazol- 2-yl)-1H-indazol-3-yl]-3-phenylurea and 3-phenylthiourea Derivatives
Medicinal Chemistry Subcellular Imaging and Diagnosis of Cancer using Engineered Nanoparticles
Current Pharmaceutical Design The Prominent Role of Protein-Based Delivery Systems on the Development of Cancer Treatment
Current Pharmaceutical Design Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models
Anti-Cancer Agents in Medicinal Chemistry The Coronin Family and Human Disease
Current Protein & Peptide Science 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity
Anti-Cancer Agents in Medicinal Chemistry Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology